Omaha, Nebraska, United States The company was established in North America in United States. The main office of represented VC is situated in the Omaha.
We also calculated 3 valuable employees in our database.
The typical case for the fund is to invest in rounds with 7-8 participants. Despite the Eventide Asset Management, startups are often financed by Third Rock Ventures, Wellcome Trust, The Column Group. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, EcoR1 Capital, TPG Biotech. In the next rounds fund is usually obtained by Zealand Pharma, TPG, Sofinnova Investments.
The increased amount of exits for fund were in 2019. The fund is generally included in 2-6 deals every year. The usual things for fund are deals in the range of 50 - 100 millions dollars. The high activity for fund was in 2019. Comparing to the other companies, this Eventide Asset Management performs on 15 percentage points more the average number of lead investments. Considering the real fund results, this VC is 2 percentage points more often commits exit comparing to other organizations.
We can highlight the next thriving fund investment areas, such as Medical Device, Health Diagnostics. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has exact preference in a number of founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Beta Bionics, Magenta Therapeutics, Karuna Therapeutics For fund there is a match between the location of its establishment and the land of its numerous investments - United States.
Related Funds
| Fund Name | Location |
| Affentranger Associates | Switzerland, Zürich, Zurich |
| BCI Europe | - |
| Caloga | France, Ile-de-France, Paris |
| ChinaVest | China, Shanghai |
| Creation Capital | Austin, Texas, United States |
| DOEN Participaties | Amsterdam, Noord-Holland, The Netherlands |
| Dongfang Economics Equity Investment Fund Management | China, Guangdong, Shenzhen |
| Horizon Discovery | Cambridge, Cambridgeshire, United Kingdom |
| LD Capital | China, Shanghai, Shanghai |
| Mamadoo Ventures | Gelderland, Netherlands, Rheden |
| ModusLink Global Solutions | Massachusetts, United States, Waltham |
| Netflix | California, Los Gatos, United States |
| PacifiCare Health Systems | California, Cypress, United States |
| Shenyang Xunan Technology | China, Liaoning, Shenyang |
| Sjova | Gullbringusysla, Iceland, Reykjavík |
| Verus International | New York, New York, United States |
| Vocap Ventures | Atlanta, Georgia, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
PreciseDx | $20M | 21 Aug 2024 | New York, New York, United States | ||
Sudo Biosciences | $30M | 13 Feb 2024 | Menlo Park, California, United States | ||
Sudo Biosciences | $116M | 20 Dec 2023 | Menlo Park, California, United States | ||
Flare Therapeutics | $123M | 22 Mar 2023 | Cambridge, Massachusetts, United States | ||
Beta Bionics | $57M | 17 Feb 2022 | Boston, Massachusetts, United States | ||
Shoreline Biosciences | $140M | 02 Nov 2021 | San Diego, California, United States | ||
DiCE Molecules | $60M | 24 Aug 2021 | California, United States | ||
Kojin Therapeutics | $60M | 09 Jun 2021 | Cambridge, Massachusetts, United States | ||
Flare Therapeutics | $82M | 13 May 2021 | Cambridge, Massachusetts, United States |
– DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, announced the completion of its $60 million Series C-1 financing.
– The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital.
– Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round.
– With the closing of this Series C-1 financing round, the Company has raised approximately $200 million to date.
– Turnstone Biologics Corp. announced the successful completion of an $80m Series D financing co-led by PFM Health Sciences and Point72.
– New investors include Eventide Asset Management, Surveyor Capital (a Citadel company), Ridgeback Capital Investments, Takeda Ventures, CaaS Capital, JM Family Enterprises, Inc., Northleaf Capital Partners, 404 Bio and an undisclosed investor.
– The round was joined by existing investors Versant Ventures, OrbiMed, F-Prime Capital, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital.
– Proceeds from the financing will be used to advance Turnstone’s pipeline of programs from its oncolytic virus and TIL therapy platforms.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
PreciseDx | $20M | 21 Aug 2024 | New York, New York, United States | ||
Sudo Biosciences | $30M | 13 Feb 2024 | Menlo Park, California, United States | ||
Sudo Biosciences | $116M | 20 Dec 2023 | Menlo Park, California, United States | ||
Flare Therapeutics | $123M | 22 Mar 2023 | Cambridge, Massachusetts, United States | ||
Beta Bionics | $57M | 17 Feb 2022 | Boston, Massachusetts, United States | ||
Shoreline Biosciences | $140M | 02 Nov 2021 | San Diego, California, United States | ||
DiCE Molecules | $60M | 24 Aug 2021 | California, United States | ||
Kojin Therapeutics | $60M | 09 Jun 2021 | Cambridge, Massachusetts, United States | ||
Flare Therapeutics | $82M | 13 May 2021 | Cambridge, Massachusetts, United States |
